search
Back to results

Efficacy of T2259 in DED

Primary Purpose

Dry Eye Syndromes

Status
Completed
Phase
Not Applicable
Locations
France
Study Type
Interventional
Intervention
T2259
Vismed multi
Sponsored by
Laboratoires Thea
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional other trial for Dry Eye Syndromes

Eligibility Criteria

18 Years - undefined (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • Signed and dated informed consent
  • Male or female aged from ≥ 18 years old
  • Known Dry Eye Syndrome requiring artificial tears within the last 3 months

Exclusion Criteria:

  • Far best-corrected visual acuity≤2/10
  • Severe Blepharitis

Sites / Locations

  • C.H.N.O des XV-XX

Arms of the Study

Arm 1

Arm 2

Arm Type

Experimental

Active Comparator

Arm Label

T2259

Vismed Multi

Arm Description

1 drop in each eye 2 to 4 times daily

1 drop in each eye 2 to 4 times daily

Outcomes

Primary Outcome Measures

evaluation of ocular staining grade
Oxford score

Secondary Outcome Measures

Full Information

First Posted
March 12, 2019
Last Updated
July 6, 2021
Sponsor
Laboratoires Thea
search

1. Study Identification

Unique Protocol Identification Number
NCT03874429
Brief Title
Efficacy of T2259 in DED
Official Title
Comparison of the Performance and Safety of T2259 Versus Vismed Multi in Dry Eye Patients With Superficial Keratitis.
Study Type
Interventional

2. Study Status

Record Verification Date
September 2020
Overall Recruitment Status
Completed
Study Start Date
February 5, 2019 (Actual)
Primary Completion Date
February 12, 2021 (Actual)
Study Completion Date
March 25, 2021 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Laboratoires Thea

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
No

5. Study Description

Brief Summary
The purpose of this study is to compare the performance and safety of T2259 versus Vismed Multi in dry eye patients with superficial keratitis.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Dry Eye Syndromes

7. Study Design

Primary Purpose
Other
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Masking
ParticipantInvestigator
Allocation
Randomized
Enrollment
90 (Actual)

8. Arms, Groups, and Interventions

Arm Title
T2259
Arm Type
Experimental
Arm Description
1 drop in each eye 2 to 4 times daily
Arm Title
Vismed Multi
Arm Type
Active Comparator
Arm Description
1 drop in each eye 2 to 4 times daily
Intervention Type
Device
Intervention Name(s)
T2259
Other Intervention Name(s)
HA and Trealose
Intervention Description
HA and Trealose
Intervention Type
Device
Intervention Name(s)
Vismed multi
Other Intervention Name(s)
HA
Intervention Description
HA
Primary Outcome Measure Information:
Title
evaluation of ocular staining grade
Description
Oxford score
Time Frame
Day 35

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Signed and dated informed consent Male or female aged from ≥ 18 years old Known Dry Eye Syndrome requiring artificial tears within the last 3 months Exclusion Criteria: Far best-corrected visual acuity≤2/10 Severe Blepharitis
Facility Information:
Facility Name
C.H.N.O des XV-XX
City
Paris
ZIP/Postal Code
75012
Country
France

12. IPD Sharing Statement

Learn more about this trial

Efficacy of T2259 in DED

We'll reach out to this number within 24 hrs